Atypical Antipsychotics for MDD Augmentation: Choosing the Right Option?
When it comes to managing Major Depressive Disorder (MDD), the challenge often lies in patients who do not fully respond to first-line treatments like SSRIs or SNRIs. For these patients, augmentation with atypical antipsychotics can be an effective strategy. But with several options available, which one should you choose?
The choice of atypical antipsychotic for MDD augmentation ultimately depends on the individual patient’s needs, the side effect profile of the medication, and any comorbid conditions.Â
Watch this brief video, which is a small excerpt from one of the chapters in our CME Academy’s inaugural course: Mastering Major Depressive Disorder Psychopharmacology.
This comparison is just a snapshot of the detailed content available in our CME course, “Mastering Major Depressive Disorder Psychopharmacology.” If you’re looking to deepen your understanding of MDD treatment strategies and earn CME credits, this course is for you.
Enroll today to gain access to comprehensive modules on MDD management, including more in-depth discussions on atypical antipsychotics, first-line treatments, and personalized care approaches.
CME ACADEMY #1
MASTERING
MAJOR DEPRESSIVE DISORDER
PSYCHOPHARMACOLOGY
TOTAL CREDITS: 8.50 AMA PRA CATEGORY 1 CREDITS
LEARNING OBJECTIVES:
- Evaluate the pharmacological mechanisms and clinical efficacy of various antidepressants used in treating Major Depressive Disorder (MDD).
- Apply evidence-based strategies to optimize antidepressant selection and dosing, tailored to individual patient profiles.Â
- Integrate adjunctive treatment options to enhance therapeutic outcomes in patients with treatment-resistant depression.
- Differentiate between various antidepressants in terms of their pharmacokinetics, efficacy, and side effect profiles.
© 2025 All Rights Reserved.
